Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,305 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT07591051 | Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer(WARP) | not yet recruiting | N/A | 54 | University of ZurichOTHER | 2 | Aug 21, 2026 |
| clinicaltrials |
| NCT06870799 | Comparing Closed Face Masks vs Surface Guided Radiation Therapy for Head and Neck Radiotherapy(NoMask) | recruiting | N/A | 25 | University of ZurichOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT05945732 | DESTINY Breast Respond HER2-(Ultra)Low Europe | recruiting | — | 2,295 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07682558 | Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management(NoDoubt) | not yet recruiting | Phase 3 | 318 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT03965468 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC(CHESS) | active not recruiting | Phase 2 | 96 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 17, 2026 | clinicaltrials |
| NCT06358573 | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | recruiting | Phase 2 | 61 | Swiss Cancer InstituteOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309) | active not recruiting | Phase 2 | 252 | AmgenINDUSTRY | 16 | Aug 17, 2026 | clinicaltrials |
| NCT03742895 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | active not recruiting | Phase 2 | 329 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 14, 2026 | clinicaltrials |
| NCT04230759 | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group(RADIANCE) | active not recruiting | Phase 2 | 180 | Goethe UniversityOTHER | 3 | Aug 14, 2026 | clinicaltrials |
| NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | completed | Phase 2 | 122 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT07762911 | Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)(Visioning III) | recruiting | N/A | 300 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT06801899 | ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer(ToPanc) | recruiting | N/A | 170 | Insel Gruppe AG, University Hospital BernOTHER | 2 | Aug 12, 2026 | clinicaltrials |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma(FIGHT-302) | terminated | Phase 3 | 167 | Incyte CorporationINDUSTRY | 19 | Aug 11, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT04739761 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer(DESTINY-B12) | active not recruiting | Phase 3 | 506 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab(ROSY-D) | enrolling by invitation | Phase 3 | 214 | AstraZenecaINDUSTRY | 31 | Aug 11, 2026 | clinicaltrials |
| NCT05916313 | A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | recruiting | Phase 1 | 20 | Boehringer IngelheimINDUSTRY | 6 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07672314 | Bridging the Gap in Psychosocial Care for Cancer Survivors(BRIDGE) | recruiting | N/A | 50 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | active not recruiting | Phase 1 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery(OPBC-10/ NOAX) | recruiting | N/A | 1,060 | University Hospital, Basel, SwitzerlandOTHER | 11 | Aug 7, 2026 | clinicaltrials |
| NCT00777582 | Phase I Comparative Bioavailability Study | active not recruiting | Phase 1 | 197 | AstraZenecaINDUSTRY | 4 | Aug 6, 2026 | clinicaltrials |
| NCT02102165 | AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.(AURORA) | recruiting | N/A | 1,000 | Jules Bordet InstituteOTHER | 10 | Aug 6, 2026 | clinicaltrials |
| NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)(MYSTIC) | active not recruiting | Phase 3 | 1,118 | AstraZenecaINDUSTRY | 17 | Aug 6, 2026 | clinicaltrials |
| NCT05261399 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment(SAFFRON) | active not recruiting | Phase 3 | 341 | AstraZenecaINDUSTRY | 27 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT07750444 | Underweight, Overweight, and Linear Growth of Childhood Cancer Patients - the Growth Study(Growth) | active not recruiting | — | 12,150 | Fabiën BelleOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06923774 | European Real-World Registry for Use of the Ion Endoluminal System | recruiting | — | 1,200 | Intuitive SurgicalINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT07415668 | Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning(MENTOR) | recruiting | N/A | 30 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03972072 | MRI - Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer (MARTHA-trial)(MARTHA) | completed | N/A | 49 | Panagiotis BalermpasOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | active not recruiting | Phase 3 | 714 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 31, 2026 | clinicaltrials |
| NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. | not yet recruiting | Phase 2 | 108 | Swiss Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials